

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute, and is not intended to be, an invitation or offer to acquire, purchase or subscribe for, or offer to sell or a solicitation of any offer to buy securities in Hong Kong, the United States or elsewhere. Any such offer or invitation will be made only in jurisdictions in which it may be legally and validly made. Securities may not be offered or sold in the United States absent registration with the U.S. Securities and Exchange Commission (the “SEC”) or an exemption from registration. An effective shelf registration statement on Form F-3, which includes a prospectus (the “**Base Prospectus**”), relating to the public offering of American Depositary Shares (“ADSs”) of Legend Biotech Corporation (“**Legend Biotech**”) has been filed by Legend Biotech with the SEC and is effective. Any public offering of ADSs to be made in the United States will be made solely by means of a prospectus supplement to the Base Prospectus that may be obtained from Legend Biotech and that contains or incorporates by reference detailed information about the company and management, as well as financial statements of Legend Biotech.*

*Neither this announcement nor any content contained herein shall form the basis of any contract or commitment whatsoever.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司 \***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1548)**

**COMPLETION OF THE  
(1) FOLLOW-ON PUBLIC OFFERING BY  
LEGEND BIOTECH CORPORATION, AND  
(2) DISCLOSEABLE CONNECTED TRANSACTION  
IN RELATION TO THE PURCHASE BY THE COMPANY  
IN THE FOLLOW-ON PUBLIC OFFERING**

This announcement is made by the board of directors (the “**Board**”) of GenScript Biotech Corporation (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated 15 December 2021, 17 December 2021, and 19 December 2021 in relation to, among other things, the Follow-on Public Offering and discloseable connected transaction in relation to the purchase by the Company in the Follow-on Public Offering (the “**GenScript Participation**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those in the previous announcements.

The Board is pleased to announce that Legend Biotech Corporation (“**Legend Biotech**”), a non-wholly owned subsidiary of the Company, whose shares are listed by way of American Depositary Shares (“**ADSs**”) on the Nasdaq Global Select Market in the United States, informed the Company that the Follow-on Public Offering, including the GenScript Participation, has been closed on 20 December 2021 (New York time) (after trading hours on 20 December 2021, Hong Kong time). Legend Biotech issued 8,615,575 ADSs in the Follow-on Public Offering, each representing two ordinary shares, at a public offering price of US\$40.00 per ADS. The number of ADSs issued at closing included the underwriters exercising their option to purchase 1,115,575 additional ADSs.

Immediately upon closing of the Follow-on Public Offering including the GenScript Participation, the shareholding of the Company in Legend Biotech has been diluted and reduced from approximately 58.41% to 56.61% (without taking into account shares to be issued under the employee share option schemes) on a fully diluted basis. Legend Biotech will continue to be a direct non-wholly owned subsidiary of the Company, and the financial results of Legend Biotech will continue to be consolidated into the financial statements of the Company upon completion of the Follow-on Public Offering.

## **GENERAL**

**Shareholders and potential investors of the Company should therefore exercise caution when dealing in or investing in the securities of the Company.**

By order of the Board  
**Genscript Biotech Corporation**  
**Meng Jiange**  
*Chairman and Executive Director*

Hong Kong, 21 December 2021

*As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.*

\* *For identification purposes only*